Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Oct 19, 2021 10:00 AM - Oct 20, 2021 5:00 PM

(US Eastern Standard Time)

DIA Canadian Annual Meeting

The Canadian Annual Meeting now includes a track for Pharmacovigilence and Risk Management Strategies!

Session 1 Track C: Pharmacovigilance and Risk Management Post-Pandemic: Lessons Learned and Future Perspectives

Session Chair(s)

Marilyne  Chamoun, MSc

Marilyne Chamoun, MSc

Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau

Health Canada, Canada

Patrick  Fandja, MBA, MS

Patrick Fandja, MBA, MS

Director, Bureau of Biologics, Radiopharmaceuticals and Self-care products

Health Canada, Canada

In this session, representatives from regulatory agencies (EMA, FDA and Health Canada) will discuss their perspectives on lessons learned from the pandemic, and how they will shape the future of pharmacovigilance and risk management planning.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Gain a global understanding of the lessons learned from the pandemic
  • Identify changes to PV/RM practices that should be adopted/considered post-pandemic

Speaker(s)

Kate A Browne, MSc, RPh

Speaker

Kate A Browne, MSc, RPh

European Medicines Agency, Netherlands

Signal Management Lead

Gerald  Dal Pan, MD, MHS

Speaker

Gerald Dal Pan, MD, MHS

FDA, United States

Director, Office of Surveillance and Epidemiology, CDER

Kelly  Robinson, MSc

Speaker

Kelly Robinson, MSc

Health Canada, Canada

Director General, Marketed Health Products Directorate

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.